Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.

Autor: Calabretta E; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., di Trani M; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Corrado F; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Sollini M; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Cristaldi V; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Marino F; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Terzi di Bergamo L; Laboratory of Experimental Hematology, Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland., Bruscaggin A; Laboratory of Experimental Hematology, Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland., Pirosa MC; Laboratory of Experimental Hematology, Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland.; Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Bramanti S; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Chiti A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Rossi D; Laboratory of Experimental Hematology, Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland.; Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Carlo-Stella C; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Feb; Vol. 204 (2), pp. 514-524. Date of Electronic Publication: 2023 Oct 18.
DOI: 10.1111/bjh.19162
Abstrakt: Reliable biomarkers for early identification of treatment failure in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL) are lacking. Circulating tumour DNA (ctDNA) profiling has emerged as a powerful predictive and prognostic tool in several haemopoietic and non-haemopoietic malignancies and may guide rational treatment choices in r/r cHL. To assess the predictive and prognostic value of ctDNA, we performed a retrospective analysis on 55 r/r cHL patients treated with the bendamustine, gemcitabine and vinorelbine (BEGEV) regimen and additionally evaluated the potential utility of integrating ctDNA with interim [ 18 F]-FDG positron emission tomography (iPET). Baseline ctDNA genotyping in r/r cHL mirrored gene mutations and pathways involved in newly diagnosed cHL. We found that baseline ctDNA quantification and serial ctDNA monitoring have prognostic value in r/r cHL receiving salvage chemotherapy. Lastly, integrating ctDNA quantification with iPET evaluation may improve the early identification of patients at high risk of failing standard salvage therapy, who may benefit from an early switch to immunotherapeutic agents. Collectively, our results support the implementation of non-invasive methods to detect minimal residual disease in recurrent cHL and justify its prospective evaluation in appropriately designed clinical trials.
(© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: